Oxigene, a biopharmaceutical company, nearly doubled in a single day, boosted by its anti ovarian cancer drugs

Source: big wisdom astak news agency on Wednesday, March 13, 2014, oxigene (NASDAQ: oxgn), a biopharmaceutical manufacturer, rose nearly 78%, leading the Nasdaq market The company's second phase of clinical trials of anti ovarian cancer drugs performed well, boosting its share price Oxigene shares surged 77.27% to close at $4.29 The biggest increase was 123.14% In recent two trading days, its share price has risen by 108.25%, beating the market by a large margin Oxigene said on the news that the second stage clinical experiment of the combination of zybrestat, an anti ovarian cancer drug, and Avastin, an anti-cancer drug under Roche pharmaceutical, showed that compared with the single use of Avastin, the combined use of the efficacy has reached the goal of "greatly improving the non deteriorating survival period" In the future, it will continue to track the development of clinical patients so as to obtain overall survival data.